安特里斯科技

最新新闻

• 评级变动
  Anteris Technologies Raised to Buy From Spec Buy by Bell Potter AVR.AU
  Dow Jones · 2026/3/9
• Anteris Technologies Global(AVR.US) 10% Shareholder Sells US$5.79 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  Barclays Maintains Anteris Technologies Global(AVR.US) With Buy Rating, Raises Target Price to $18
  \u5e02\u573a\u8d44\u8baf · 2026/5/15
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL), Cogent Biosciences (COGT) and Anteris Technologies Global Corp. (AVR)
  TipRanks · 2026/6/1
• 评级变动
  Barclays Maintains Anteris Technologies Global(AVR.US) With Buy Rating, Raises Target Price to $22
  \u5e02\u573a\u8d44\u8baf · 2026/2/24
• 评级变动
  Wells Fargo Initiates Anteris Technologies Global(AVR.US) With Buy Rating, Announces Target Price $16
  \u5e02\u573a\u8d44\u8baf · 2026/3/11
• 评级变动
  Anteris Technologies Global Corp. (AVR) Gets a Buy From Barclays
  TipRanks · 2026/2/24
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Anteris Technologies Global Corp. (AVR) and Siemens Healthineers AG (OtherSEMHF)
  TipRanks · 2026/5/4
• 评级变动
  TD Cowen Maintains Anteris Technologies Global(AVR.US) With Buy Rating, Maintains Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2026/6/30
• Wells Fargo Maintains Anteris Technologies Global(AVR.US) With Buy Rating, Maintains Target Price $16
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  Cantor Fitzgerald Sticks to Their Buy Rating for Anteris Technologies Global Corp. (AVR)
  TipRanks · 2026/5/14
• 评级变动
  Barclays Reaffirms Their Buy Rating on Anteris Technologies Global Corp. (AVR)
  TipRanks · 2026/5/15
• Anteris Technologies Global(AVR.US) 10% Shareholder Buys US$6.71 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/10/6
• 评级变动
  Barclays Maintains Anteris Technologies Global(AVR.US) With Buy Rating, Cuts Target Price to $17
  \u5e02\u573a\u8d44\u8baf · 2026/3/12
• Anteris Technologies Global(AVR.US) 10% Shareholder Buys US$3.03 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• Barclays Downgrades Anteris Technologies Global(AVR.US) to Hold Rating, Cuts Target Price to $10
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Anteris Technologies Global Corp. (AVR) and Kymera Therapeutics (KYMR)
  TipRanks · 2026/6/26
• 评级变动
  Cantor Fitzgerald Remains a Buy on Anteris Technologies Global Corp. (AVR)
  TipRanks · 2026/8/14
• 评级变动
  Analysts Conflicted on These Healthcare Names: Anteris Technologies Global Corp. (AVR), Lifecore Biomedical (LFCR) and Biogen (BIIB)
  TipRanks · 2026/6/18
• 评级变动
  Analysts Offer Insights on NA Companies: BETA Technologies, Inc. Class A (BETA) and Anteris Technologies Global Corp. (AVR)
  TipRanks · 2026/8/13

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。